2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Strattec reported fiscal fourth-quarter 2026 sales of $151.8 million, roughly flat from $152.0 million a year earlier, and GAAP diluted earnings per share of $0.95 versus $2.01. For the full fiscal year, sales rose to $579.4 million from $565.1 million and gross margin expanded to 16.5% from 15.0%, while the company authorized a new $40 million share buyback.
Q4 net income attributable to Strattec was $3.9 million, or $0.95 per diluted share, versus $8.3 million, or $2.01, a year earlier; adjusted diluted EPS was $2.06, unchanged.
Q4 gross margin fell to 15.6% from 16.7%; Q4 Adjusted EBITDA was $12.5 million versus $13.0 million.
Fiscal 2026 Adjusted EBITDA was $50.5 million, a 15.3% increase over the prior year.
The company had $108.2 million in cash and no debt at June 28, 2026, and repurchased $7.4 million of shares in the fourth quarter.
Ensysce Biosciences said Nasdaq determined on August 25, 2026 that it complies with the $2.5 million stockholders' equity requirement, but the company remains subject to delisting if it does not evidence compliance in its next periodic report. Nasdaq also granted an extension on the minimum bid price rule to February 22, 2027, and said the Cy Biopharma transaction triggers a change of control requiring the post-transaction company to meet initial listing criteria, with trading suspension possible if it does not.
Nasdaq determined on August 25, 2026 that the company complies with the $2.5 million stockholders' equity requirement, but delisting remains possible if compliance is not evidenced in the next periodic report
Nasdaq granted an additional 180 calendar days, until February 22, 2027, to regain the $1.00 minimum bid price requirement
Nasdaq said the Cy Biopharma transaction, completed August 5, 2026, is a change of control requiring an initial listing application; failure could lead to trading suspension
The company intends to submit an initial listing application in a timely manner
QumulusAI reported unaudited results for the quarter ended June 30, 2026, its first quarterly report since trading on the Nasdaq Global Market began July 16, 2026. Revenue rose 118% year over year to $6.7 million, but the company posted a net loss of $22.8 million, compared with net income of $12.1 million a year earlier, due in part to a $19.2 million non-cash loss on convertible notes.
Revenue of $6.7 million, up 118% from $3.1 million; gross margin 67% versus 55%
Operating loss of $7.7 million versus $2.2 million, driven by a $5.8 million rise in depreciation and amortization
Net loss of $22.8 million, or $0.72 per share, versus net income of $12.1 million
Signed 21 new direct customer contracts with aggregate expected take-or-pay value of $169.7 million
Electromed reported record fiscal 2026 results, with net revenues up 15.3% to $73.8 million and net income up to $11.3 million, or $1.30 per diluted share. The company also said CEO and director Jim Cunniff plans to retire on or about April 2, 2027, and the board has begun a search for his successor.
FY 2026 net revenues rose 15.3% to $73.8 million; operating income rose 43.7% to $13.9 million
Q4 FY 2026 net income rose 54.3% to $3.4 million, or $0.39 per diluted share
Cash from operations fell to $9.7 million from $11.4 million; the company repurchased $3.9 million of stock
CEO Jim Cunniff expects to retire on or about April 2, 2027 and will leave the board upon retirement
Intuit reported fiscal 2026 fourth-quarter revenue of $4.4 billion, up 14%, and full-year revenue of $21.4 billion, up 14%. Fourth-quarter GAAP operating income rose to $475 million from $339 million, but the company booked a $293 million restructuring charge and GAAP diluted EPS was $1.34 versus $1.35 a year earlier. The company also gave fiscal 2027 guidance for revenue of $23,279 million to $23,512 million, and its board approved a $1.38 quarterly dividend.
Q4 FY2026 total revenue was $4.4 billion, up 14%; full-year GAAP diluted EPS was $16.46, up 20%.
Q4 GAAP operating income was $475 million, including a $293 million restructuring charge; Q4 GAAP diluted EPS was $1.34 versus $1.35 a year earlier.
FY2027 GAAP revenue guidance is $23,279 million to $23,512 million; non-GAAP guidance now includes share-based compensation.
Quarterly dividend of $1.38 per share is payable October 16, 2026, to holders of record on October 8, 2026.
Quad/Graphics filed slides for presentations at the Midwest IDEAS Conference on August 26, 2026. The deck shows second-quarter 2026 net sales of $577.5 million, up from $571.9 million a year earlier, while adjusted EBITDA fell to $42.0 million from $43.3 million. Net debt leverage rose to 2.03x at June 30, 2026, from 1.57x at December 31, 2025.
Q2 2026 net sales were $577.5 million, compared with $571.9 million in Q2 2025.
Q2 2026 adjusted EBITDA was $42.0 million (7.3% margin), compared with $43.3 million (7.6% margin) in Q2 2025.
Q2 2026 adjusted diluted EPS was $0.24, compared with $0.14 in Q2 2025; net earnings were $3.7 million versus a $0.1 million loss.
Net Debt Leverage Ratio was 2.03x at June 30, 2026, versus 1.57x at December 31, 2025; the 2026 guidance range for adjusted EBITDA is $175 million to $215 million.
Marzetti reported fourth-quarter and fiscal 2026 results for the period ended June 30, 2026. Quarterly net sales fell 2.2% to $465.0 million, while net income rose to $48.3 million, helped by an $18.5 million gain on the sale of its Milpitas, California, property, and adjusted diluted EPS rose 9.0% to $1.46. For shareholders the picture is mixed: reported quarterly sales declined and part of the profit gain came from the one-time property gain, though fiscal 2026 net income rose to $191.6 million and operating cash flow reached a record $283.8 million.
Fourth-quarter net sales were $465.0 million, down 2.2%, or up 0.4% excluding $12.2 million of prior-year temporary supply agreement sales with Winland Foods.
The Bachan's acquisition, which closed May 1, 2026, added $15.4 million of fourth-quarter Retail segment sales.
Fiscal 2026 net income was $191.6 million, or $6.98 per diluted share, versus $6.07 a year earlier; adjusted diluted EPS was $6.83 versus $6.72.
Fiscal 2026 cash dividends totaled $108.8 million and share repurchases totaled $36.3 million; the company increased its regular dividend for the 63rd consecutive year.
SelectQuote reported fourth-quarter fiscal 2026 revenue of $321.7 million, down from $345.1 million a year earlier, and a net loss of $16.8 million, compared with net income of $12.9 million in the prior-year quarter. Adjusted EBITDA rose to $11.9 million from $2.7 million, and cash used in operations narrowed to $3.3 million from $37.5 million. The company also gave fiscal 2027 guidance of $1.35 billion to $1.45 billion in revenue and $90 million to $115 million in Adjusted EBITDA.
Q4 fiscal 2026 revenue was $321.7 million versus $345.1 million in Q4 fiscal 2025; net loss was $16.8 million versus net income of $12.9 million
Q4 Adjusted EBITDA was $11.9 million versus $2.7 million a year earlier; fiscal 2026 Adjusted EBITDA was $109.1 million versus $126.3 million
Fiscal 2026 net income was $62.2 million and operating cash flow was $31.9 million, a $44 million improvement over fiscal 2025
Fiscal 2027 guidance: revenue of $1.35 billion to $1.45 billion, Adjusted EBITDA of $90 million to $115 million, and operating cash flow of more than $60 million
DICK'S reported second-quarter 2026 GAAP net sales of $5.6 billion, up from $3.6 billion a year earlier, mainly because of the Foot Locker acquisition, while GAAP earnings per diluted share fell 26% to $3.50. The company lowered its full-year 2026 Foot Locker comparable sales and operating income outlook, citing challenging athletic footwear conditions, but kept its DICK'S Business comparable sales outlook unchanged, which matters to shareholders because Foot Locker now makes up a large share of results.
Q2 GAAP EPS $3.50 vs. $4.71 a year earlier; non-GAAP EPS $3.53 vs. $4.38; 9.6 million shares issued for Foot Locker dilute per-share results.
DICK'S Business comparable sales rose 4.9%; Foot Locker proforma comparable sales fell 3.6%.
Full-year 2026 outlook: Foot Locker comparable sales now negative 2.0% to 0.0% and Foot Locker segment loss of $(80) million to $(40) million; DICK'S comparable sales outlook maintained at 2.5% to 4.0%.
Quarterly dividend of $1.25 per share, payable September 25, 2026, to holders of record on September 11, 2026.
Madison Air Solutions agreed to sell 90,108,130 Class A common shares at $24.97 each in a private placement expected to bring in about $2.25 billion before fees, with closing expected on or about September 1, 2026. The company says the proceeds will fully fund the equity portion of its acquisition of ebm-papst entities, for which estimated total cash payable at closing is $5.0 billion. Chairman Larry Gies and an affiliated entity, Madison Solutions LLC, are buying a combined $620.0 million of the shares, and the filing notes the sale may dilute existing stockholders.
Sale of 90,108,130 Class A shares at $24.97 per share, with gross proceeds expected to be about $2.25 billion
Larry Gies agreed to buy $300.0 million of shares; Madison Solutions LLC agreed to buy $320.0 million
Expected closing on September 1, 2026; proceeds fund the equity portion of the ebm-papst acquisition, with estimated total cash payable at closing of $5.0 billion
Shares must be registered for resale within 90 calendar days after closing; Gies and Madison Solutions shares are locked up for one year
Citi Trends reported second-quarter fiscal 2026 net sales up 10.9% to $211.6 million, with comparable store sales up 10.5%. The company posted a net loss of $0.9 million, or $0.11 per diluted share, compared with net income of $3.8 million a year earlier, which included an $11.0 million gain on a building sale. It raised its fiscal 2026 adjusted EBITDA outlook to $38 million to $42 million, which signals higher expected profitability for the year.
Q2 net sales of $211.6 million rose $20.9 million, or 10.9%, from Q2 2025; comparable store sales rose 10.5%.
Q2 net loss of $0.9 million ($0.11 per diluted share) compares with net income of $3.8 million ($0.46 per diluted share) in Q2 2025, which included an $11.0 million gain on the Savannah office building sale.
Fiscal 2026 adjusted EBITDA outlook raised to $38 million to $42 million from $35 million to $40 million; comparable store sales growth outlook raised to 9% to 11%.
First-half net income was $6.8 million; cash was $55.9 million at quarter-end with no debt.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.